Metformina + Vildagliptina Alter

Metformin Hydrochloride and Vildagliptin, the active ingredients in Metformina + Vildagliptina Alter, are a biguanide and a DPP‑4 inhibitor presented as oral tablets for oral use. They are employed to improve glycaemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Metformina + Vildagliptina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina Alter is used in the management of type 2 diabetes and related hyperglycaemic conditions. - Type 2 diabetes mellitus: improves blood glucose control when combined with diet and exercise. - Hyperglycaemia in adults: reduces fasting and post‑prandial glucose levels. - Metabolic syndrome (as part of combination therapy): assists in achieving target HbA1c.

Metformina + Vildagliptina Alter may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: frequent loose stools, especially at treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Headache: mild to moderate intensity. - Upper respiratory tract infection: occasional cold‑like symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic failure: marked liver enzyme elevation. - Renal impairment: worsening kidney function.

When prescribing Metformina + Vildagliptina Alter, clinicians should consider several safety aspects. - Renal function: assess eGFR before initiation and monitor periodically. - Hepatic impairment: use with caution and observe liver enzyme trends. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia or severe infection. - Pregnancy and lactation: evaluate risk‑benefit; limited data are available. - Drug interactions: review concomitant medicines for potential interactions. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformina + Vildagliptina Alter can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to risk of lactic acidosis. - Iodinated contrast agents: discontinue metformin before and after imaging to prevent accumulation. - Co‑administration with other DPP‑4 inhibitors: duplication of effect should be avoided. - Strong CYP2C9 inhibitors: may increase Vildagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Sulfonylureas: heightened risk of hypoglycaemia; adjust dose as needed. - Beta‑blockers: may mask hypoglycaemia symptoms, requiring vigilant glucose monitoring. - Diuretics: can affect renal function, necessitating periodic assessment of kidney parameters.